Painful sex due to menopause is common, but every woman's preference is unique
Audrey worries that vaginal creams and gels may be a barrier to sexual spontaneity.
Karen is uncomfortable with the feeling left by vaginal creams and gels.
Valerie prefers taking a once-daily oral pill.
Ava wants a hormone-free treatment option.
Judy prefers a treatment that does not require vaginal insertion of an applicator.
You and your healthcare provider should talk regularly (every 3 to 6 months) about the dose you are taking and whether or not you still need treatment with Osphena®.
Although your preference should be considered, your healthcare provider must determine appropriate treatment for you based on your medical history and current condition, as well as on the potential side effects of individual treatment options.
Patient profiles are based on: Krychman M, Graham S, Bernick B, et al. The Women’s EMPOWER Survey: Women’s Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate. J Sex Med 2017;14:425e433; Kingsberg S, Krychman M, Graham S, et al. The Women’s EMPOWER Survey: Identifying Women’s Perceptions on Vulvar and Vaginal Atrophy and Its Treatment. J Sex Med 2017; 14:413e424; Kingsberg SA, Wysocki S, Magnus L, and Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: Findings from the REVIVE (REal Women’s Views of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med; and Wysocki S, Kingsberg S, Krychman M. Management of Vaginal Atrophy: Implications from the REVIVE Survey. Clinical Medicine Insights Reproductive Health. 2014;8:23-30. doi:10.4137/CMRH.S14498.